---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-011005"
form_type: "8-K"
ticker: "LXEO"
cik: "0001907108"
company_name: "Lexeo Therapeutics, Inc."
filed_at: "2024-02-05T23:59:59+00:00"
generated_at: "2026-06-06T09:25:02.939545+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lexeo appoints CDO, CMO, Senior Advisor, and Chief Business & Legal Officer

## Summary
- Sandi See Tai promoted to Chief Development Officer; previously VP at Pfizer, led tafamidis ATTR-ACT program.
- Eric Adler appointed Chief Medical Officer & Head of Research; former CSO at Lexeo, UCSD professor, gene therapy pioneer.
- Rajiv Patni named Senior Advisor to CEO & Board; former CRO at Reata (acquired by Biogen), led Skyclarys approval.
- Jenny Robertson promoted to Chief Business and Legal Officer; previously Chief Legal & Admin Officer, Pfizer rare disease counsel.

## SEC filing metadata
- accession: 0000950170-24-011005
- form_type: 8-K
- ticker: LXEO
- cik: 0001907108
- company_name: Lexeo Therapeutics, Inc.
- filed_at: 2024-02-05T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907108/000095017024011005/0000950170-24-011005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907108/000095017024011005/lxeo-20240205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-011005
- JSON: https://secwatch.observer/filing/0000950170-24-011005.json
- Plain text: https://secwatch.observer/filing/0000950170-24-011005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.